Kineta Garners $760,497 New Funding

  • Feed Type
  • Date
    10/10/2013
  • Company Name
    Kineta
  • Mailing Address
    219 Terry Ave N Seattle, WA 98109
  • Company Description
    Through Kineta, our pioneering team is dedicated to further study of innate immunity with an aggressive strategy to develop early stage programs for powerful new antiviral and immune modulating drugs. We believe our unique approach will yield a new class of drugs to respond to diseases caused by viruses such as, Influenza, Hepatitis C and West Nile virus: diseases that afflict millions of people.
  • Website
    http://www.kinetabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $760,497
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Not a solicitation.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.